Affinity DataIC50: 0.100nMAssay Description:Inhibitory concentration against Cyclin dependent kinase 1More data for this Ligand-Target Pair
Affinity DataIC50: 0.900nMAssay Description:Inhibitory concentration against Cyclin dependent kinase 1More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibitory concentration against Cyclin dependent kinase 1More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: 3nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibitory concentration against Cyclin dependent kinase 1More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: 4nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Inhibitory concentration against Cyclin dependent kinase 1More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Inhibitory concentration against Cyclin dependent kinase 1More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Inhibitory concentration against Cyclin dependent kinase 1More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:Inhibitory concentration against Cyclin dependent kinase 1More data for this Ligand-Target Pair
Affinity DataIC50: 9nMAssay Description:Inhibitory concentration against Cyclin dependent kinase 1More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: 9nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
Affinity DataIC50: 9nMAssay Description:Inhibitory concentration against Cyclin dependent kinase 1More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:Inhibitory concentration against Cyclin dependent kinase 1More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:Inhibitory concentration against Cyclin dependent kinase 1More data for this Ligand-Target Pair
Affinity DataIC50: 11nMAssay Description:Inhibitory concentration against Cyclin dependent kinase 1More data for this Ligand-Target Pair
Affinity DataIC50: 14nMAssay Description:Inhibitory concentration against Cyclin dependent kinase 1More data for this Ligand-Target Pair
Affinity DataIC50: 15nMAssay Description:Inhibitory concentration against Cyclin dependent kinase 1More data for this Ligand-Target Pair
Affinity DataIC50: 15nMAssay Description:Inhibitory concentration against Cyclin dependent kinase 1More data for this Ligand-Target Pair
Affinity DataIC50: 22nMAssay Description:Inhibitory concentration against Cyclin dependent kinase 1More data for this Ligand-Target Pair
Affinity DataIC50: 25nMAssay Description:Inhibitory concentration against Cyclin dependent kinase 1More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: 25nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
Affinity DataIC50: 29nMAssay Description:Inhibitory concentration against Cyclin dependent kinase 4More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
TargetVoltage-dependent N-type calcium channel subunit alpha-1B(Homo sapiens (Human))
Nosopharm
US Patent
Nosopharm
US Patent
Affinity DataIC50: <30nMAssay Description:Interaction with N-type calcium channels was assessed with radiolabelled a competitive binding assay, applying the procedure described by Wagner et a...More data for this Ligand-Target Pair
Affinity DataIC50: 32nMAssay Description:Inhibitory concentration against Cyclin dependent kinase 1More data for this Ligand-Target Pair
Affinity DataIC50: 34nMAssay Description:Inhibitory concentration against Cyclin dependent kinase 1More data for this Ligand-Target Pair
Affinity DataIC50: 34nMAssay Description:Inhibitory concentration against Cyclin dependent kinase 1More data for this Ligand-Target Pair
Affinity DataIC50: 43nMAssay Description:Inhibitory concentration against Cyclin dependent kinase 1More data for this Ligand-Target Pair
Affinity DataIC50: 57nMAssay Description:Inhibitory concentration against Cyclin dependent kinase 4More data for this Ligand-Target Pair
Affinity DataIC50: 57nMAssay Description:Inhibitory concentration against Cyclin dependent kinase 4More data for this Ligand-Target Pair
Affinity DataIC50: 77nMAssay Description:Inhibitory concentration against Cyclin dependent kinase 1More data for this Ligand-Target Pair
Affinity DataIC50: 126nMAssay Description:Inhibitory concentration against Cyclin dependent kinase 1More data for this Ligand-Target Pair